SCR7 pyrazine
CAT:
804-HY-107845-05
Size:
25 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
SCR7 pyrazine
- CAS Number: 14892-97-8
- UNSPSC Description: SCR7 pyrazine is a DNA ligase IV inhibitor that blocks nonhomologous end-joining (NHEJ) in a ligase IV-dependent manner. SCR7 pyrazine is also a CRISPR/Cas9 enhancer which increases the efficiency of Cas9-mediated homology-directed repair (HDR). SCR7 pyrazine induces cell apoptosis and has anticancer activity[1][2].
- Target Antigen: Apoptosis; CRISPR/Cas9; DNA/RNA Synthesis
- Type: Reference compound
- Related Pathways: Apoptosis;Cell Cycle/DNA Damage
- Applications: Cancer-Kinase/protease
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/scr7-pyrazine.html
- Purity: 99.96
- Solubility: DMSO : 100 mg/mL (ultrasonic)
- Smiles: O=C1NC(NC2=NC(C3=CC=CC=C3)=C(C4=CC=CC=C4)N=C12)=S
- Molecular Weight: 332.38
- References & Citations: [1]Srivastava M, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 2012 Dec 21;151(7):1474-87.|[2]Lin C, et al. Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells. Sci Rep. 2016 Oct 7;6:34531.Int J Mol Sci. 2022, 23(14), 7518.|BMC Biotechnol. 2021 Jul 27;21(1):45.|EMBO Rep. 2019 Mar;20(3):e46821.|J Genet Genomics. 2021 Mar 30.|J Immunol. 2020 Apr 1;204(7):1904-1918.|J Immunother Cancer. 2022 Jan;10(1):e003809.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Mol Ther Nucleic Acids. 2024 Jul 17;35(3):102274.|Onco Targets Ther. 2018 Aug 17;11:4945-4953.|Sens Actuators B Chem. 19 February 2022, 131598.|Stem Cell Res Ther. 2024 Dec 2;15(1):458.|Viruses. 2023 Nov 14, 15(11), 2256.
- Shipping Conditions: Room Temperature
- Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
- Clinical Information: No Development Reported